Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FM3Q
|
|||
| Drug Name |
PMID28454500-Compound-33
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H20N2O3
|
|||
| Canonical SMILES |
CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC(=O)C=CC3=CC=CC=C3
|
|||
| InChI |
1S/C21H20N2O3/c1-15(24)22-12-11-17-14-23-20-9-8-18(13-19(17)20)26-21(25)10-7-16-5-3-2-4-6-16/h2-10,13-14,23H,11-12H2,1H3,(H,22,24)/b10-7+
|
|||
| InChIKey |
NDJABQJCUZPRSD-JXMROGBWSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cysteines of Keap1 (KEAP1 Cysteines) | Target Info | Modulator | [1] |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Activator | [1] | |
| Target's Patent Info | Cysteines of Keap1 (KEAP1 Cysteines) | Target's Patent Info | [1] | |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.